Monoclonal Antibody Clinical Trials

A listing of Monoclonal Antibody medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
Featured trial
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer  

This phase I trial evaluates the effects of CBM588 in combination with standard therapies, nivolumab and cabozantinib, in treating patients with kidney cancer that has spread to other places in the body (advanced/metastatic). The digestive microbiome may have an effect on how patients respond to treatment, and previous research shows …

  • 0 views
  • 14 Mar, 2022
  • 1 location
Randomised Evaluation of COVID-19 Therapy (RECOVERY)  

RECOVERY is a randomised trial investigating whether treatment with Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Infliximab, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) prevents death in patients with COVID-19.

  • 0 views
  • 14 Sep, 2022
  • 6 locations
Safety Tolerability and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198

This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

monoclonal antibodies
body mass index
  • 0 views
  • 16 Feb, 2024
  • 1 location
Safety Tolerability and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

This is a phase 1 study in which healthy adult volunteers will receive BRII-196 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

monoclonal antibodies
body mass index
  • 0 views
  • 16 Feb, 2024
  • 1 location
Safety Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection

This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-5 Humanized Monoclonal Antibody injection in Healthy Subjects. There are 6 Groups as follows: 0.03mg/kg (S1), 0.2mg/kg (S2), 1.0mg/kg (S3), 3.0mg/kg (S4), 5.0mg/kg (S5) and 7.5mg/kg (S6); and 2 subjects were included in the S1 group (both received study drugs); 10 …

  • 0 views
  • 16 Feb, 2024
  • 1 location
Safety Tolerability and Pharmacokinetics of SCTA01 an Anti-SARS-CoV-2 Monoclonal Antibody in Healthy Chinese Subjects

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.

  • 0 views
  • 05 Aug, 2020
Tolerability Safety Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese healthy subjects after intravenous infusion of single dose.Eligible patients will be injection JS016 (anti-SARS-CoV-2 monoclonal antibody)

  • 0 views
  • 16 Feb, 2024
  • 1 location
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery in Recurrent Glioblastoma

This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM).

karnofsky performance status
major surgery
oral contraceptives
monoclonal antibodies
growth factor
  • 0 views
  • 16 Feb, 2024
  • 1 location
PTX-35 in Patients With Advanced Solid Tumors

A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care

metastasis
antibody therapy
monoclonal antibodies
neutrophil count
unresectable solid tumor
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Antibodies

pd-l1
monoclonal antibodies
antibody therapy
growth factor
small cell lung cancer
  • 0 views
  • 16 Feb, 2024
  • 8 locations